A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Huang, Fei ^a   Mazin, Alexander V ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 2 [2 (PYRIDIN 3 YL)VINYL]QUINAZOLIN 4(3H)ONE; B 02; CISPLATIN; DOXORUBICIN; ETOPOSIDE; PROTEIN INHIBITOR; RAD51 PROTEIN; TOPOTECAN; UNCLASSIFIED DRUG; (E)-3-BENZYL-2-(2-(PYRIDIN-3-YL) VINYL) QUINAZOLIN-4(3H)-ONE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; QUINAZOLINONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG STRUCTURE; DRUG TARGETING; EMBRYO; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG SCREENING; FEMALE; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CISPLATIN; DOXORUBICIN; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, NUDE; QUINAZOLINONES; RAD51 RECOMBINASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903396205     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100993     Document Type: Article

References (47)

1. Moynahan ME, Jasin M (2010) Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 11: 196-207.
2. Bianco PR, Tracy RB, Kowalczykowski SC (1998) DNA strand exchange proteins: a biochemical and physical comparison. Front Biosci 3: D570-603.
3. Symington LS, Gautier J (2011) Double-strand break end resection and repair pathway choice. Annu Rev Genet 45: 247-271.
4. San Filippo J, Sung P, Klein H (2008) Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 77: 229-257.
5. Gonzalez-Prieto R, Munoz-Cabello AM, Cabello-Lobato MJ, Prado F (2013) Rad51 replication fork recruitment is required for DNA damage tolerance. Embo J 32: 1307-1321.
6. Raderschall E, Golub EI, Haaf T (1999) Nuclear foci of mammalian recombination proteins are located at single-stranded DNA regions formed after DNA damage. Proc Natl Acad Sci U S A 96: 1921-1926. (Pubitemid 29117843)
7. Curtin NJ (2012) DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 12: 801-817.
8. Helleday T (2010) Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 31: 955-960.
9. Powell SN, Bindra RS (2009) Targeting the DNA damage response for cancer therapy. DNA Repair (Amst) 8: 1153-1165.
10. Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396: 643-649. (Pubitemid 29003936)
11. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, et al. (2002) Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 62: 219-225. (Pubitemid 34074008)
12. Xia SJ, Shammas MA, Shmookler Reis RJ (1997) Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase. Mol Cell Biol 17: 7151-7158. (Pubitemid 27505945)
13. Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, et al. (2000) Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. International Journal of Cancer 88: 907-913.
14. Klein HL (2008) The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst) 7: 686-693.
15. Tennstedt P, Fresow R, Simon R, Marx A, Terracciano L, et al. (2013) RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. Int J Cancer 132: 2118-2126.
16. Mao Z, Jiang Y, Liu X, Seluanov A, Gorbunova V (2009) DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells. Neoplasia 11: 683-691.
17. Hannay JA, Liu J, Zhu QS, Bolshakov SV, Li L, et al. (2007) Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther 6: 1650-1660. (Pubitemid 46954032)
18. Brown ET, Holt JT (2009) Rad51 overexpression rescues radiation resistance in BRCA2-defective cancer cells. Mol Carcinog 48: 105-109.
19. Sandell LL, Zakian VA (1993) Loss of a yeast telomere: arrest, recovery, and chromosome loss. Cell 75: 729-739. (Pubitemid 23346371)
20. Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, et al. (2005) Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 7: 1044-1052. (Pubitemid 41195066)
21. Kiyohara E, Tamai K, Katayama I, Kaneda Y (2012) The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma. Gene Ther 19: 734-741.
22. Huang F, Motlekar NA, Burgwin CM, Napper AD, Diamond SL, et al. (2011) Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol 6: 628-635.
23. Huang F, Mazina OM, Zentner IJ, Cocklin S, Mazin AV (2012) Inhibition of homologous recombination in human cells by targeting RAD51 recombinase. J Med Chem 55: 3011-3020.
24. Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, et al. (2013) Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther 12: 2043-2054.
25. Foltz CJ, Ullman-Cullere M (1999) Guidelines for Assessing the Health and Condition of Mice. Lab Anim 28: 28-32. (Pubitemid 129631140)
26. Abengozar MA, de Frutos S, Ferreiro S, Soriano J, Perez-Martinez M, et al. (2012) Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. Blood 119: 4565-4576.
27. Koehn H, Magan N, Isaacs RJ, Stowell KM (2007) Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin. Anticancer Drugs 18: 419-425. (Pubitemid 46712405)
28. Keimling M, Wiesmuller L (2009) DNA double-strand break repair activities in mammary epithelial cells-influence of endogenous p53 variants. Carcinogenesis 30: 1260-1268.
29. Sharom FJ (1997) The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 160: 161-175.
30. Pampaloni F, Reynaud EG, Stelzer EH (2007) The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 8: 839-845. (Pubitemid 47462131)
31. Wiseman H, Halliwell B (1996) Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 313 (Pt 1): 17-29. (Pubitemid 26013419)
32. Bartkova J, Bakkenist CJ, Rajpert-De Meyts E, Skakkebaek NE, Sehested M, et al. (2005) ATM activation in normal human tissues and testicular cancer. Cell Cycle 4: 838-845. (Pubitemid 41353838)
33. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, et al. (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907-913. (Pubitemid 40559004)
34. Taki T, Ohnishi T, Yamamoto A, Hiraga S, Arita N, et al. (1996) Antisense inhibition of the RAD51 enhances radiosensitivity. Biochem Biophys Res Commun 223: 434-438. (Pubitemid 26245585)
35. Ohnishi T, Taki T, Hiraga S, Arita N, Morita T (1998) In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochemical & Biophysical Research Communications 245: 319-324. (Pubitemid 28418498)
36. Lord CJ, Ashworth A (2012) The DNA damage response and cancer therapy. Nature 481: 287-294.
37. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross- linking agent cisplatin. J Biol Chem 275: 23899-23903. (Pubitemid 30624678)
38. Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R (2005) Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther 314: 495-505. (Pubitemid 41043829)
39. Turchi JJ, Henkels KM, Zhou Y (2000) Cisplatin-DNA adducts inhibit translocation of the Ku subunits of DNA-PK. Nucleic Acids Res 28: 4634-4641.
40. Kocher S, Spies-Naumann A, Kriegs M, Dahm-Daphi J, Dornreiter I (2013) ATM is required for the repair of Topotecan-induced replication-associated double-strand breaks. Radiother Oncol 108: 409-414.
41. Schonn I, Hennesen J, Dartsch DC (2011) Ku70 and Rad51 vary in their importance for the repair of doxorubicin- versus etoposide-induced DNA damage. Apoptosis 16: 359-369.
42. Guengerich FP (2008) Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21: 70-83.
43. Budke B, Kalin JH, Pawlowski M, Zelivianskaia AS, Wu M, et al. (2013) An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. J Med Chem 56: 254-263.
44. Budke B, Logan HL, Kalin JH, Zelivianskaia AS, Cameron McGuire W, et al. (2012) RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res 40: 7347-7357.
45. Ishida T, Takizawa Y, Kainuma T, Inoue J, Mikawa T, et al. (2009) DIDS, a chemical compound that inhibits RAD51-mediated homologous pairing and strand exchange. Nucleic Acids Res 37: 3367-3376.
46. Takaku M, Kainuma T, Ishida-Takaku T, Ishigami S, Suzuki H, et al. (2011) Halenaquinone, a chemical compound that specifically inhibits the secondary DNA binding of RAD51. Genes Cells 16: 427-436.
47. Choudhury A, Zhao H, Jalali F, Al Rashid S, Ran J, et al. (2009) Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther 8: 203-213.